On July 23, 2020, Revance Therapeutics, Inc. completed its previously announced acquisition of Hint, Inc. pursuant to that certain Agreement and Plan of Merger, dated as of May 18, 2020 by and among Revance, Heart Merger Sub, Inc. and Fortis Advisors LLC. At the Effective Time, Aubrey Rankin, the Chief Executive Officer of HintMD, was appointed by the board of directors of Revance to serve as a director of Revance and as Revance’s President of Innovation & Technology. Mr. Rankin was designated as a Class III director whose term expires at the Revance’s 2023 Annual Meeting of Stockholders. As an employee of Revance, Mr. Rankin will not be eligible to receive additional compensation for his service as a director under Revance’s Non-Employee Director Compensation Policy.